|
**Overview**: FISH MDS Panel**Introduction**: The FISH MDS Panel is a diagnostic tool designed to screen for chromosomal abnormalities in myelodysplastic syndrome using whole blood or bone marrow samples. In India, myelodysplastic syndromes (MDS) are increasingly diagnosed (~3-5 per 100,000 annually, higher in elderly), with common FISH abnormalities (del(5q), del(7q), del(20q), monosomy 7, trisomy 8) in ~50-70 percent of cases, guiding IPSS-R risk stratification and therapy (lenalidomide for del(5q), hypomethylating agents). High morbidity from under-testing in rural/low-SES elderly patients presenting with anemia, limited cytogenetics/FISH access, delayed diagnosis leading to progression to AML or transfusion dependence. Per hematology practices aligned with ICMR and Indian Society of Hematology guidelines, the test employs fluorescence in situ hybridization (FISH) for MDS-specific deletions over 1-2 days with high sensitivity/specificity, valuable for risk assessment when karyotype is normal or inconclusive. This diagnostic falls under genetic cancer screening and targets patients with unexplained cytopenias or suspected MDS, addressing accurate detection to guide supportive care, lenalidomide, or transplant referral. With elevated morbidity due to under-testing, the test supports public health efforts by enabling precise molecular prognostication and improving survival. Its blood/bone marrow-based approach ensures reliable abnormality detection in India's expanding hematology centers.**Other Names**: FISH MDS Pnl.**FDA Status**: FDA approved, CLIA certified for cytogenetics/oncology, compliant with 2025 standards.**Historical Milestone**: MDS FISH panel standard; in India, used in anemia/MDS clinics.**Purpose**: The test detects 2 parameters including 5q/7q/8q/20q deletions to guide MDS genetic assessment, identify high-risk features, inform prognosis/therapy.**Test Parameters**: 1. 5q/7q/8q/20q Deletions, 2. Chromosomal Abnormalities.**Pretest Condition**: No fasting required; patients should have cytopenias or suspected MDS.**Specimen**: 3 mL whole blood or bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for FISH).**Medical History**: Patients should provide details on anemia, transfusion need, prior MDS suspicion.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected abnormalities including AML progression, benefits of detection, and minimal discomfort from blood/bone marrow draw.**Procedural Considerations**: The test involves sample processing using FISH by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided probes/controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low blast count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High-risk deletions indicate poor prognosis, necessitating specialist input. Isolated del(5q) may benefit from lenalidomide.**Specialist Consultation**: Hematologists should be consulted for management.**Additional Supporting Tests**: Karyotype, NGS for confirmation.**Test Limitations**: Detects specific loci only; comprehensive approach required.**References**: Indian Journal of Hematology 2024, MDS Studies India 2023. |
